T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Ingredion
INGR
$6.63B
| $15.1M | ﹤0.01% |
136,564
+7,085
| +5% | +$799K |
|
1127
Petrobras Class A
PBR.A
$104B
| $15M | ﹤0.01% |
1,331,789
| – | – |
|
1128
AES
AES
$10.5B
| $15M | ﹤0.01% |
1,046,159
+3,418
| +0.3% | +$48.2K |
|
|
ECHO
1129
EchoStar
ECHO
$26.6B
| $15M | ﹤0.01% |
137,869
+7,337
| +6% | +$597K |
|
1130
Norwegian Cruise Line
NCLH
$8.98B
| $15M | ﹤0.01% |
669,992
+11,169
| +2% | +$236K |
|
|
SEI
1131
Solaris Energy Infrastructure
SEI
$3.94B
| $14.8M | ﹤0.01% |
321,448
-406,925
| -56% | -$19.7M |
|
1132
Advanced Energy
AEIS
$13.2B
| $14.7M | ﹤0.01% |
70,145
+35,641
| +103% | +$7.25M |
|
1133
Mine Safety
MSA
$7.32B
| $14.7M | ﹤0.01% |
91,480
-301,744
| -77% | -$49.1M |
|
1134
Moderna
MRNA
$25.4B
| $14.6M | ﹤0.01% |
494,013
+11,148
| +2% | +$303K |
|
1135
Baxter International
BAX
$14B
| $14.6M | ﹤0.01% |
761,411
-12,690,881
| -94% | -$254M |
|
1136
Charles River Laboratories
CRL
$13.4B
| $14.5M | ﹤0.01% |
72,856
| – | – |
|
1137
BlackLine
BL
$1.82B
| $14.5M | ﹤0.01% |
262,811
+1,588
| +0.6% | +$87.5K |
|
1138
CarGurus
CARG
$3.38B
| $14.4M | ﹤0.01% |
376,648
-1,254
| -0.3% | -$45.2K |
|
|
NBIS
1139
Nebius Group N.V.
NBIS
$69.3B
| $14.4M | ﹤0.01% |
172,564
+102,986
| +148% | +$10.7M |
|
1140
UroGen Pharma
URGN
$2.34B
| $14.4M | ﹤0.01% |
616,606
+259,991
| +73% | +$5.64M |
|
1141
iShares Core MSCI EAFE ETF
IEFA
$196B
| $14.4M | ﹤0.01% |
160,781
-4,818
| -3% | -$426K |
|
|
WCC
1142
WESCO International
WCC
$17.5B
| $14.3M | ﹤0.01% |
58,501
+4,866
| +9% | +$1.19M |
|
1143
Simply Good Foods
SMPL
$989M
| $14.2M | ﹤0.01% |
705,176
+10,291
| +1% | +$214K |
|
1144
Ryan Specialty Holdings
RYAN
$11B
| $14.1M | ﹤0.01% |
273,113
+8,166
| +3% | +$448K |
|
1145
A.O. Smith
AOS
$8.49B
| $14.1M | ﹤0.01% |
210,688
-17,809
| -8% | -$1.2M |
|
|
ETOR
1146
eToro Group
ETOR
$2.3B
| $14.1M | ﹤0.01% |
399,937
+291,985
| +270% | +$11.3M |
|
1147
Kinsale Capital Group
KNSL
$8.59B
| $14M | ﹤0.01% |
35,910
+705
| +2% | +$287K |
|
1148
Relay Therapeutics
RLAY
$4.37B
| $13.9M | ﹤0.01% |
1,645,403
+507,722
| +45% | +$3.62M |
|
1149
Tetra Tech
TTEK
$9.33B
| $13.9M | ﹤0.01% |
413,523
+18,676
| +5% | +$632K |
|
1150
Glaukos
GKOS
$11.2B
| $13.8M | ﹤0.01% |
122,169
+5,263
| +5% | +$503K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.